| abstract |
Pyrroloazepine derivatives represented by general formula (I) or salts thereof, wherein the ring P shown by (1) means a pyrrole ring represented by (2) or (3) (where R1 represents alkyl, cycloalkyl, etc., and R2 represents H or alkyl); the dotted line represents the presence or absence of a bond; when the bond is present, then Z2 is absent and Z1 represents H; when the bond is absent, then Z1 and Z2 each represents H, Z1 represents H and Z2 represents a group represented by OR3 (where R3 represents H, alkyl, aralkyl, etc.), Z1 and Z2 each represents a group represented by SR4 (where R4 represents alkyl, aralkyl, etc.), or Z1 and Z2 are combined to represent O, a group represented by NOR5 (where R5 represents H, alkyl, etc.), or C2-3 alkylenedithio; A represents alkylene, alkenylene, or alkynylene; and Y represents a group represented by (4) (where W represents CH, C= or N; m is 0 or 1; n is 1, 2, or 3; G represents O, S, C=O, sulfinyl, sulfonyl, alkylene, alkenylene, acetal, etc.; E1 and E2 each represents H or lower alkyl; and D represents aromatic hydrocarbyl or heteroaryl). The compounds (I) have a potent serotonium-2 receptor antagonism, are reduced in toxicity and side effects, and are useful therapeutic agents for circulatory diseases such as ischemic heart diseases, cerebrovascular disorders; and peripheral circulatory disturbances. |